

Immunosuppressant Treatment for Systemic Lupus Erythematosus

Micheal Ibrahim*

Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland

DESCRIPTION

Systemic LE (SLE) is that the commonest sort of lupus. SLE is an autoimmune disorder during which the system attacks its own tissues, causing widespread inflammation and tissue damage within the affected organs. It can affect the joints, skin, brain, lungs, kidneys, and blood vessels. An disease caused when the system attacks its own tissues.

Lupus (SLE) can affect the joints, skin, kidneys, blood cells, brain, heart and lungs.

Symptoms vary but can include fatigue, joint pain, rash and fever. These can periodically worsen (flare up) then improve.

While there is no cure for lupus, current treatments specialise in improving quality of life through controlling symptoms and minimising flare-ups. This begins with lifestyle modifications, including sun protection and diet. Further disease management includes medication like anti-inflammatories and steroids [1].

Systemic LE (SLE) may be a chronic autoimmune disorder. SLE is characterized by the assembly of bizarre antibodies within the blood. The cause(s) of systemic LE is (are) unknown, however, heredity, viruses, ultraviolet, and medicines all may play some role.

SLE can affect multiple components of the system, including the-

Complement system (i.e, a neighborhood of the system that enhances the power of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, promote inflammation, and attack the pathogen's cell membrane), T-suppressor cells, Cytokine production.

Emerging evidence has demonstrated a key player within the generation of autoantigens in SLE is that the increase in generation (i.e. increased apoptosis) and/or decrease in clearance of apoptotic cell materials (i.e., decreased phagocytosis).

Results in generation of autoantibodies, which can circulate for several years before the event of overt clinical SLE. The disease tends to possess a relapsing and remitting course.

SYMPTOMS

Symptoms are Butterfly-shaped rash, Raised red patches on your skin, You're sensitive to light, Ulcers in your mouth or nose, Arthritis in two or more joints, plus swelling or tenderness, Inflammation within the lining of your heart or lungs, Seizures or other nerve problems, an excessive amount of protein in your urine, Low blood corpuscle counts, Certain antibodies in your blood.

CAUSES

The explanation for SLE isn't clearly known. It's going to be linked to the subsequent factors: Genetic, Environmental, Hormonal, Certain medicines [2]. SLE is more common in women than men by nearly 10 to 1. It's going to occur at any age. However, it appears most frequently in young women between the ages of 15 and 44. In the US, the disease is more common in African Americans, Asian Americans, African Caribbeans, and Hispanic Americans.

DIAGNOSIS

Your doctor will do a physical exam to see for typical signs and symptoms of lupus, including: sun sensitivity rashes, like a malar or butterfly rash. Mucous membrane ulcers, which can occur within the mouth or nose. arthritis, which is swelling or tenderness of the tiny joints of the hands, feet, knees, and wrists, hair loss, hair thinning, signs of cardiac or lung involvement, like murmurs, rubs, or irregular heartbeats.

No one single test is diagnostic for SLE, but screenings which will help your doctor come to an informed diagnosis include: blood tests, like antibody tests and an entire blood count, a urinalysis, a chest X-ray. Your doctor might refer you to a rheumatologist, which may be a doctor who focuses on treating joint and soft tissue disorders and autoimmune diseases.

TREATMENT

There is no permanent cure for SLE. The goal of treatment is to alleviate symptoms and protect organs by decreasing inflammation and/or the extent of autoimmune activity within the body. The precise treatment is set on a private basis. Many of

Corresponding author: Micheal Ibrahim, Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. Email: micheal@652.com

Received date: December 3, 2020; **Accepted date:** December 17, 2020; **Published date:** December 24, 2020

Citation: Ibrahim M (2020) Immunosuppressant Treatment for Systemic Lupus Erythematosus. J Vaccines Vaccin. S8: e002.

Copyright: © 2020 Ibrahim M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

us with mild symptoms may have no treatment or only intermittent courses of anti-inflammatory medications [3]. Those with more serious illness involving damage to internal organ(s) may require high doses of corticosteroids together with other medications that suppress the body's system.

To protect from sun sensitivity, sunscreens, sun avoidance, and sun protection clothing are used. Certain sorts of lupus rash can answer topical cortisone medications - Nonsteroidal anti-inflammatory drugs (NSAIDs), Antimalarial drugs, Corticosteroids, Biologics, Immunosuppressants.

Drugs that suppress the system could also be helpful in serious cases of lupus. Examples include azathioprine (Imuran, Azasan), mycophenolate mofetil (CellCept) and methotrexate (Trexall).

Potential side effects may include an increased risk of infection, liver damage, decreased fertility and an increased risk of cancer. Rituximab (Rituxan) are often beneficial in cases of resistant lupus. Side effects include allergy to the intravenous infusion and infections.

REFERENCES

1. Trojánek M, Grebenyuk V, Herrmannová K, Nečas T, Gregorová J, Kucbel M, et al. A novel coronavirus (SARS-CoV-2) and COVID-19. *Cas Lek Cesk.* 2020;159(2):55-66.
2. Xie M, Chen Q. Insight into 2019 novel coronavirus—an updated in trim review and lessons from SARS-CoV and MERS-CoV. *Int J Infect Dis.* 2020;94:119-124.
3. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell.* 2020;181:271-280.